A new trading day began on Monday, with Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock price up 9.59% from the previous day of trading, before settling in for the closing price of $5.84. RXRX’s price has ranged from $3.79 to $12.36 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -35.28%. Meanwhile, its annual earnings per share averaged 13.54%. With a float of $330.56 million, this company’s outstanding shares have now reached $399.15 million.
In terms of profitability, gross margin is -0.08%, operating margin of -960.64%, and the pretax margin is -962.73%.
Recursion Pharmaceuticals Inc (RXRX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 23.50%, while institutional ownership is 56.96%. The most recent insider transaction that took place on Mar 27 ’25, was worth 836,987. In this transaction Chief Executive Officer of this company sold 138,574 shares at a rate of $6.04, taking the stock ownership to the 1,117,450 shares. Before that another transaction happened on Mar 27 ’25, when Company’s Officer proposed sale 138,574 for $6.04, making the entire transaction worth $836,987.
Recursion Pharmaceuticals Inc (RXRX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.52% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Here are Recursion Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 46.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.78, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.15 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Looking closely at Recursion Pharmaceuticals Inc (NASDAQ: RXRX), its last 5-days average volume was 41.9 million, which is a jump from its year-to-date volume of 25.35 million. As of the previous 9 days, the stock’s Stochastic %D was 66.05%.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 53.27%, which indicates a significant decrease from 68.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.44 in the past 14 days, which was lower than the 0.45 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.93, while its 200-day Moving Average is $6.24.
